BGMSP
Bio Green Med Pref·NASDAQ
--
--(--)
--
--(--)
0.36 / 10
Underperform
BSX's fundamental evaluation is weak (0.4/10). Key concerns include a negative ROA (-38.97%) and a negative net profit margin (-51.95%), which outweigh the positive fixed assets turnover ratio (1.227). This imbalance justifies the defensive rating and suggests limited upside in the near term.
Analysis Checks(1/4)
ROA (%)
Value-38.97
Score0/3
Weight52.82%
1M Return-4.91%
Value-38.97
Score0/3
Weight52.82%
1M Return-4.91%
Fixed assets turnover ratio
Value1.23
Score3/3
Weight-59.97%
1M Return3.36%
Value1.23
Score3/3
Weight-59.97%
1M Return3.36%
Total profit (YoY growth rate %)
Value76.47
Score0/3
Weight54.32%
1M Return-3.71%
Value76.47
Score0/3
Weight54.32%
1M Return-3.71%
Annualized net profit margin on total assets (%)
Value-51.95
Score0/3
Weight52.82%
1M Return-4.91%
Value-51.95
Score0/3
Weight52.82%
1M Return-4.91%
ROA (%)
Value-38.97
Score0/3
Weight52.82%
1M Return-4.91%
Value-38.97
Score0/3
Weight52.82%
1M Return-4.91%
Total profit (YoY growth rate %)
Value76.47
Score0/3
Weight54.32%
1M Return-3.71%
Value76.47
Score0/3
Weight54.32%
1M Return-3.71%
Fixed assets turnover ratio
Value1.23
Score3/3
Weight-59.97%
1M Return3.36%
Value1.23
Score3/3
Weight-59.97%
1M Return3.36%
Annualized net profit margin on total assets (%)
Value-51.95
Score0/3
Weight52.82%
1M Return-4.91%
Value-51.95
Score0/3
Weight52.82%
1M Return-4.91%
Is BGMSP fundamentally strong?
- BGMSP scores 0.36/10 on fundamentals and holds a Premium valuation at present. Backed by its -159.37% ROE, 0.00% net margin, -0.07 P/E ratio, 0.07 P/B ratio, and 99.74% earnings growth, these metrics solidify its Underperform investment rating.
